| Ticker |
AMRX
|
| CIK | 0001723128 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | N/A |
| Website | amneal.com |
| Phone | (908) 947-3120 |
| CEO | Chintu Patel |
| Employees | 7,600 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
1 Small-Cap Stock with Competitive Advantages and 2 We Turn DownMany small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors. The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Biosimilar XOLAIR FDA Submission – Learn WhyAmneal Pharmaceuticals recently announced the submission of a Biologics License Application to the U.S. FDA for a proposed biosimilar to XOLAIR®, a leading therapy with approximately US$4.1 billion in annual U.S. sales, and will present at the MVIC inhalation symposium this week. This BLA submission advances Amneal's biosimilar ambitions while the company also gains recognition from analysts as an attractive value stock within its industry. We'll examine how the potential entry into the... A Look at Amneal Pharmaceuticals’s Valuation After XOLAIR Biosimilar Submissions and Recent Analyst UpgradesAmneal Pharmaceuticals (AMRX) caught investors’ attention after announcing regulatory submissions in the U.S. and Europe for a biosimilar to XOLAIR. This move taps into a multibillion-dollar market and expands its biosimilar pipeline. See our latest analysis for Amneal Pharmaceuticals. After the FDA and EMA submissions for its XOLAIR biosimilar, Amneal Pharmaceuticals has seen momentum build in its share price, with a 35% year-to-date share price return and a remarkable three-year total... Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in FocusAmneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations. |
